title: Single dose of H3 receptor antagonist--ciproxifan--abolishes negative effects of chronic stress on cognitive processes in rats.
abstract: BACKGROUND
  The role of histamine neurons in stress evoked cognitive impairments remains unclear. Previous research has indicated that the blockade of H(3)-type histamine receptors may improve attention and memory in naïve rodents.
  
  
  OBJECTIVE
  The purpose of this study was to determine if ciproxifan, (cyclopropyl-(4-(3-1H-imidazol-4-yl) propyloxy) phenyl) ketone, an H(3) receptor antagonist, could alleviate cognitive deficits observed in chronically stressed rats.
  
  
  METHODS
  Specifically, we attempted to characterize the preventive action of single dose of ciproxifan (3 mg/kg, i.p.) against an impairment caused by chronic restraint stress (2 h daily for 21 days) on recognition memory tested in an object recognition task and on the long-term memory tested in a passive avoidance test.
  
  
  RESULTS
  We found that administration of ciproxifan potently prevented deleterious effects of chronic restraint stress, when administered prior to learning, or immediately after learning, or before retrieval on both the recognition (p<0.001) and the passive avoidance behavior (p<0.001).
  
  
  CONCLUSIONS
  These data support the idea that modulation of H(3) receptors represents a novel and viable therapeutic strategy in the treatment of stress evoked cognitive impairments.
authors: Department of Clinical Pharmacology, Medical University of Bialystok, Waszyngtona 15A, 15-274, Bialystok, Poland, e_trofim@umb.edu.pl.
authors: Emil
authors: E
authors: Trofimiuk
authors: Jan J
authors: JJ
authors: Braszko
mesh_terms: D000818:Animals; D001007:Anxiety / Q000523:psychology; D001362:Avoidance Learning / Q000187:drug effects; D002908:Chronic Disease; D003071:Cognition / Q000187:drug effects* / Q000502:physiology*; D005106:Exploratory Behavior / Q000187:drug effects; D006632:Histamine / Q000378:metabolism; D054828:Histamine H3 Antagonists / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008568:Memory / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D021641:Recognition, Psychology / Q000187:drug effects; D012149:Restraint, Physical; D013315:Stress, Psychological / Q000523:psychology*; D009435:Synaptic Transmission / Q000187:drug effects
chemical_list: D054828:Histamine H3 Antagonists; D007093:Imidazoles; C115705:ciproxifan; D006632:Histamine
references: Mini Rev Med Chem. 2004 Nov;4(9):979-92
references: 15544558
references: Annu Rev Neurosci. 2002;25:433-69
references: 12052916
references: J Pharmacol Exp Ther. 2008 Jan;324(1):391-8
references: 17940197
references: Brain Res. 2001 Oct 5;915(1):108-11
references: 11578627
references: Behav Brain Res. 1987 Sep;25(3):195-203
references: 3689567
references: J Neural Transm Gen Sect. 1993;93(1):1-10
references: 8396945
references: Neuropsychopharmacology. 1999 Sep;21(3):399-407
references: 10457537
references: Neuropharmacology. 2001;40(1):106-13
references: 11077076
references: Psychopharmacology (Berl). 2009 Jan;202(1-3):141-52
references: 18493749
references: Eur J Neurosci. 2003 Dec;18(11):3069-79
references: 14656302
references: Behav Brain Res. 2001 Dec 14;127(1-2):137-58
references: 11718889
references: Br J Pharmacol. 2008 Jul;154(6):1166-81
references: 18469850
references: Brain Res Brain Res Rev. 1997 Jun;24(1):1-27
references: 9233540
references: Br J Pharmacol. 1992 Dec;107(4):919-23
references: 1334753
references: Br J Pharmacol. 1996 Dec;119(8):1656-64
references: 8982515
references: Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6):633-8
references: 2615855
references: Science. 1993 Jul 2;261(5117):104-6
references: 8391168
references: J Physiol. 1999 Mar 15;515 ( Pt 3):777-86
references: 10066904
references: J Pharmacol Exp Ther. 2002 Dec;303(3):1061-6
references: 12438528
references: Neuroscience. 2000;97(2):253-66
references: 10799757
references: Brain Res. 1990 Sep 3;526(2):322-7
references: 1979518
references: Neuroendocrinology. 1992 Sep;56(3):419-28
references: 1331840
references: Pharmacol Biochem Behav. 1986 Mar;24(3):525-9
references: 2871560
references: Neuron. 1993 Nov;11(5):837-44
references: 8240807
references: Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14002-8
references: 9391142
references: J Pharmacol Exp Ther. 2005 Apr;313(1):176-90
references: 15608077
references: FASEB J. 2005 Jul;19(9):1131-3
references: 15894564
references: J Pharmacol Exp Ther. 2003 Jun;305(3):887-96
references: 12606603
references: Behav Brain Res. 1999 Oct;104(1-2):147-55
references: 11125734
references: J Physiol. 1996 Oct 1;496 ( Pt 1):175-84
references: 8910206
references: Behav Brain Res. 2004 Sep 23;154(1):211-9
references: 15302127
references: Biochem Pharmacol. 2007 Apr 15;73(8):1084-96
references: 17129577
references: Behav Brain Res. 2001 Oct 15;124(2):235-42
references: 11640976
references: Science. 1971 Jun 4;172(3987):1037-9
references: 5573952
references: Neuroscience. 2003;118(3):853-66
references: 12710992
references: J Neurosci. 2000 Feb 15;20(4):1568-74
references: 10662846
references: J Pharmacol Exp Ther. 1998 Nov;287(2):658-66
references: 9808693
references: Curr Top Med Chem. 2011;11(6):648-60
references: 21261594
references: J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45
references: 17327487
references: Eur J Neurosci. 2002 May;15(10):1669-80
references: 12059975
references: Neuropharmacology. 2009 Jun;56(8):1131-7
references: 19345233
references: Neurobiol Learn Mem. 2001 Nov;76(3):298-313
references: 11726239
references: Psychopharmacology (Berl). 2009 Jan;201(4):483-94
references: 18762914
references: Brain Res. 1977 Jun 24;129(1):107-19
references: 871922
references: J Pharmacol Exp Ther. 2003 Jun;305(3):897-908
references: 12606600
references: Neuroscience. 2002;114(1):173-93
references: 12207964
references: Behav Brain Res. 1988 Nov 1;31(1):47-59
references: 3228475
references: Pharmacol Rep. 2005 Mar-Apr;57(2):176-87
references: 15886416